BUY NOVOSARM – S-23 (20 MG/ML – 30 ML) FOR SALE
MAIN PRODUCT DESCRIPTION
S-23 is an orally bioavailable, non-steroidal selective androgen receptor modulator (SARM) described in the supplied product information as an investigational compound associated with androgen-receptor signalling. The source discusses its potential effects on skeletal muscle, bone tissue and body composition, while also presenting a number of fitness-related claims. These claims should be distinguished from established clinical indications because the supplied information does not provide evidence of marketing authorisation or an approved therapeutic use.
Product Specifications
Product: NovoSARM – S-23
Active compound: S-23
Strength: 20 mg/ml
Pack size: 30 ml
Dosage form: Liquid preparation
Route: Oral, according to supplied information
Pharmacological class: Selective Androgen Receptor Modulator
Regulatory status: Investigational
Manufacturer: Not supplied in the source material
Pharmacological Background
S-23 belongs to the SARM class, a group of synthetic compounds developed to interact with androgen receptors. The androgen receptor is an intracellular receptor that mediates many of the biological effects of endogenous androgens such as testosterone and dihydrotestosterone.
Following receptor activation, androgen signalling can influence the transcription of genes involved in multiple physiological processes. Research into SARMs has focused on whether selective receptor activity can affect tissues such as skeletal muscle and bone while producing a different tissue profile from conventional anabolic-androgenic steroids.
The supplied information describes S-23 as a highly active androgen receptor modulator and compares it with other SARMs such as S-4 (Andarine). However, statements that S-23 is a “safer alternative” to anabolic steroids or that it is free from significant androgenic consequences should not be presented as established safety conclusions.
Research Interest in Muscle and Bone
The supplied product material associates S-23 with research into lean body mass, skeletal muscle, bone tissue, strength and endurance. These areas are relevant to the scientific interest surrounding selective androgen receptor modulation.
Androgen-receptor signalling is involved in muscle and bone physiology, which is why SARMs have been investigated for conditions in which preservation of muscle or bone may be clinically relevant.
However, the source provided does not contain sufficient verified human clinical evidence to establish S-23 as an approved treatment for muscle wasting, osteoporosis, frailty or other medical conditions.
Body Composition and Metabolic Claims
The supplied information places significant emphasis on fat reduction and body composition. It describes S-23 as potentially affecting fat mass and as being used in fitness communities for cutting, muscle definition and body recomposition.
These claims should be treated as research or marketing statements rather than established therapeutic benefits. The supplied material does not provide a validated human clinical indication for weight management or obesity treatment.
Similarly, claims that S-23 directly converts stored fat into muscle tissue should not be presented as a scientifically established mechanism.
Research on Endocrine Function
S-23 acts on the androgen receptor and therefore has the potential to influence endocrine signalling. Research into SARMs has shown that selective receptor modulation does not necessarily eliminate systemic hormonal effects.
The supplied source focuses largely on positive fitness-related claims and does not provide a comprehensive endocrine safety profile. Consequently, it would be inappropriate to describe S-23 as hormone-neutral or incapable of suppressing endogenous androgen production.
Potential effects on the hypothalamic-pituitary-gonadal axis should be considered when evaluating the compound in research settings.
Half-Life Information
The supplied source reports an approximate half-life of 12 hours for S-23. This pharmacokinetic information is presented as part of the source’s research-oriented discussion.
No additional pharmacokinetic parameters were supplied, including validated absorption, distribution or elimination data for the specific 20 mg/ml commercial presentation.
Fitness and Performance Claims
The source describes S-23 as being used for:
Muscle development
Muscle retention
Strength
Endurance
Cutting
Body recomposition
Increased muscle definition
Reduced fat mass
These statements reflect the fitness-oriented context of the supplied material. They should not be presented as established medical outcomes or as evidence that the product is an approved performance-enhancing treatment.
The source also claims that users may retain gains after a cycle and that S-23 does not cause water retention. These are not sufficiently supported by the supplied evidence to be treated as guaranteed characteristics.
Administration Information
The supplied source contains specific dosing schedules for men and women, proposed cycle lengths and timing around exercise and meals. It also describes combinations of S-23 with other SARMs, including LGD-4033, RAD-140 and MK-677.
Because S-23 is described as an investigational SARM and the supplied information does not establish an authorised human treatment regimen, those dosing schedules and stacking instructions are not reproduced as recommendations.
Combining investigational compounds may introduce additional pharmacological and endocrine effects, and no safety profile for such combinations has been supplied.
Safety Considerations
The supplied source does not provide a comprehensive adverse-reaction section, clinical contraindication list or long-term human safety assessment for S-23.
The absence of a comprehensive adverse-effect list should not be interpreted as evidence that the compound is free from adverse effects. Pharmacological activity at androgen receptors may influence reproductive, metabolic and cardiovascular systems, among others.
Claims that S-23 provides the benefits of anabolic steroids without their adverse effects should therefore be avoided.
Regulatory Status
No marketing authorisation, approved therapeutic indication, EU authorisation number or national medicinal-product licence was supplied for S-23.
Accordingly, NovoSARM – S-23 should not be described as an approved prescription medicine, an EU-authorised medicine or a clinically established treatment for muscle growth, fat loss or athletic performance.
Important Research Notice
S-23 is an investigational selective androgen receptor modulator. The supplied information discusses possible effects on muscle, bone, body composition, strength and endurance, but these statements do not establish clinical efficacy, long-term safety or regulatory approval.
This description is based solely on the product information provided and should not be interpreted as medical advice, a therapeutic recommendation or instructions for non-prescribed human use.
